PERFORMANCE / SINGLE
CJC-1295 DAC
2MG · 5MGThis content is intended for educational and research reference only and does not constitute medical advice, diagnosis, or treatment. Experimental compounds are for research use only and are not for human consumption. Always consult qualified healthcare providers before starting any therapy.
Research Overview
A GHRH analogue extended with a Drug Affinity Complex (DAC) for a longer half-life, studied in growth-hormone-axis research.
Available Strengths
- 2MG (CD2)
- 5MG (CD5)
Research Protocol
Reference weekly schedule
| Period | Dose | U-100 units | Volume |
|---|---|---|---|
| Weeks 1–12 | 2 mg | 100 | 1 mL |
Reconstitution
2.0 mg/mL once reconstituted
- Draw 1.0 mL of bacteriostatic water per 2 mg vial.
- Inject slowly along the vial wall; swirl gently until dissolved.
Research context
Binds GHRH receptors on pituitary somatotrope cells; the DAC modification extends its half-life to roughly 6–8 days in the cited research, supporting once-weekly dosing while the studies describe a preserved natural GH release rhythm.
Storage
−20°C, dry and dark. 2–8°C, use within 4 weeks, avoid freeze-thaw cycles.
Research Notes
- For educational and research reference only. Not medical advice and not intended for unsupervised human use.
References
Source reference: PeptideDosages.com · 2026-08-18 · Exact strength match with the cited source